Randomized phase II trial of combination idiotype vaccine and anti-CD3/anti-CD28 costimulated autologous T cells in patients with multiple myeloma post-autotransplantation

Muzaffar H. Qazilbash(The University of Texas MD Anderson Cancer Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Medhavi Honhar(The University of Texas MD Anderson Cancer Center), Adam D. Cohen(Penn Center for AIDS Research), Edward A. Stadtmauer(University of Pennsylvania), Alfred L. Garfall(University of Pennsylvania), Robert Z. Orlowski(University of North Carolina at Chapel Hill), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Nina Shah(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Krina K. Patel(University of Vermont), Beryl Tross(The University of Texas MD Anderson Cancer Center), Karen Dengel(Parker Institute for Cancer Immunotherapy), Qaiser Bashir(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Michael Popescu(The University of Texas MD Anderson Cancer Center), Veera Baladandayuthapani(The University of Texas MD Anderson Cancer Center), Jatin J. Shah(The University of Texas MD Anderson Cancer Center), Soung-chul Cha(The University of Texas MD Anderson Cancer Center), Naseem Kerr(Parker Institute for Cancer Immunotherapy), Sheetal Rao(The University of Texas MD Anderson Cancer Center), Carl H. June(University of Pennsylvania), Donna Weber(The University of Texas MD Anderson Cancer Center), Sheeba K. Thomas(The University of Texas MD Anderson Cancer Center)
Experimental Hematology
August 22, 2017
Cited by 5


Related Papers